on one side you have PGNX who wouldnt present there, a little early to at GU, if the trials were failures. and on the other side you have ASCO who wouldnt let PGNX, or anyone for that matter, present 2 slides if both were failures. this goes over 7 at least at that point and with all that positive news could reach about 9 by the time the ADCOM date arrives. IF Relistor gets approved this time around its going to double figures instantly and everyone will be talking about a BO
I agree with you that it is unlikely for PGNX to go to ASCO-GU to present failures. However, ASCO-GU does not require participants to present good data. Actually, the only requirement in that regard is to not disclose any data prior to the presentation. It is therefore impossible that ASCO knows the outcome of the trial beforehand.
Jan 30. with such a definitive catalyst which seems highly likely to be positive, plus the Azedra resumption and the ADCOM date, this stock could easily double from here. it was trading at 6 in Sept without the above news